Patents Assigned to AVEO Pharmaceuticals, Inc.
-
Publication number: 20140193427Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.Type: ApplicationFiled: December 20, 2013Publication date: July 10, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
-
Publication number: 20140178935Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: ApplicationFiled: October 2, 2013Publication date: June 26, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Publication number: 20140178934Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: ApplicationFiled: September 27, 2013Publication date: June 26, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: May Han, S. Kirk Wright, William M. Winston, JR., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
-
Publication number: 20140066603Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.Type: ApplicationFiled: November 1, 2013Publication date: March 6, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
-
Publication number: 20140045715Abstract: A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.Type: ApplicationFiled: August 5, 2013Publication date: February 13, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: Jie Lin, Bin Feng, Murray Robinson, Feng Jiang, Xiaojian Sun
-
Patent number: 8603478Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.Type: GrantFiled: July 6, 2011Date of Patent: December 10, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
-
Patent number: 8580930Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: August 20, 2012Date of Patent: November 12, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Patent number: 8575318Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: August 20, 2012Date of Patent: November 5, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
-
Patent number: 8481688Abstract: Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2.Type: GrantFiled: May 11, 2011Date of Patent: July 9, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: Zhigang Weng, William M. Winston, Jr., Ailin Bai, Kristan Meetze, Solly Weiler, Ting Chen, Jeno Gyuris
-
Patent number: 8481687Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: April 8, 2011Date of Patent: July 9, 2013Assignee: Aveo Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Publication number: 20130165337Abstract: Methods for identifying multigene biomarkers for predicting sensitivity or resistance to an anti-cancer drug of interest, or multigene cancer prognostic biomarkers are disclosed. The disclosed methods are based on the classification of the mammalian genome into 51 transcription clusters, i.e., non-overlapping, functionally relevant groups of genes whose intra-group transcript levels are highly correlated. Also disclosed are specific multigene biomarkers for predicting sensitivity or resistance to tivozanib, or rapamycin, and a specific multigene biomarker for determining breast cancer prognosis, all of which were identified using the methods disclosed herein.Type: ApplicationFiled: November 5, 2012Publication date: June 27, 2013Applicant: AVEO PHARMACEUTICALS, INC.Inventor: AVEO PHARMACEUTICALS, INC.
-
Publication number: 20130165343Abstract: Methods for identifying multigene biomarkers for predicting sensitivity or resistance to an anti-cancer drug of interest, or multigene cancer prognostic biomarkers are disclosed. The disclosed methods are based on the classification of the mammalian genome into 51 transcription clusters, i.e., non-overlapping, functionally relevant groups of genes whose intra-group transcript levels are highly correlated. Also disclosed are specific multigene biomarkers for predicting sensitivity or resistance to tivozanib, or rapamycin, and a specific multigene biomarker for determining breast cancer prognosis, all of which were identified using the methods disclosed herein.Type: ApplicationFiled: February 25, 2013Publication date: June 27, 2013Applicant: AVEO Pharmaceuticals, Inc.Inventor: AVEO Pharmaceuticals, Inc.
-
Patent number: 8373017Abstract: Reconstituted human breast tumor models are disclosed. The models, which are incorporated into mice, provide actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain either: (a) a recombinant human oncogene and an SV40er; or (b) a recombinant human oncogene, a transgene or shRNA that inhibits the p53 pathway, and a transgene or shRNA that inhibits the Rb pathway.Type: GrantFiled: December 6, 2005Date of Patent: February 12, 2013Assignee: AVEO Pharmaceuticals, Inc.Inventors: Min Wu, Charlotte Kuperwasser, Murray Robinson
-
Publication number: 20120302572Abstract: The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.Type: ApplicationFiled: April 25, 2012Publication date: November 29, 2012Applicants: AVEO PHARMACEUTICALS, INC., OSI Pharmaceuticals, LLCInventors: Julie Kan, Stuart Thomson, Gretchen M. Argast, Matthew E. O'Connor, Murray Robinson, Bin Feng, Joerg Heyer, Maria I. Chiu, Richard Nicoletti
-
Patent number: 8273355Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: March 18, 2011Date of Patent: September 25, 2012Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Patent number: 8268315Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: March 18, 2011Date of Patent: September 18, 2012Assignee: AVEO Pharmaceuticals, Inc.Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris
-
Patent number: 8187601Abstract: Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3.Type: GrantFiled: June 30, 2009Date of Patent: May 29, 2012Assignee: AVEO Pharmaceuticals, Inc.Inventors: Zhigang Weng, William M. Winston, Jr., Lyne Breault, Kristan Meetze, Solly Weiler, Jeno Gyuris
-
Patent number: 7998973Abstract: A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per week. In some embodiments of the invention, the tivozanib is administered on a repeating schedule of one dose per day for three weeks, followed by one week without tivozanib administration. The disclosed method is particularly suitable for treatment of renal cell carcinoma.Type: GrantFiled: August 13, 2010Date of Patent: August 16, 2011Assignee: AVEO Pharmaceuticals, Inc.Inventors: Pankaj Bhargava, W. Brooke Esteves, John L. Ryan
-
Patent number: 7943344Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: December 7, 2009Date of Patent: May 17, 2011Assignees: AVEO Pharmaceuticals, Inc., XOMA Technology Ltd.Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Patent number: 7935502Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: December 7, 2009Date of Patent: May 3, 2011Assignee: AVEO Pharmaceuticals, Inc.Inventors: May Han, S. Kirk Wright, William M. Winston, Jr., Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris